Gilder Gagnon Howe & Co’s Sana Biotechnology SANA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$314K	Sell	89,960 -5,836	-6%	-$18.8K	﹤0.01%	269
2026 Q1	$276K	Buy	95,796 +1,724	+2%	+$6.79K	﹤0.01%	246
2025 Q4	$383K	Buy	94,072 +2,533	+3%	+$11.3K	﹤0.01%	240
2025 Q3	$325K	Buy	+91,539	New	+$331K	﹤0.01%	246
2024 Q4	–	Sell	-69,291	Closed	-$288K	–	271
2024 Q3	$288K	Buy	+69,291	New	+$364K	﹤0.01%	244
2024 Q2	–	Sell	-84,259	Closed	-$843K	–	271
2024 Q1	$843K	Buy	+84,259	New	+$631K	0.01%	218
2022 Q2	–	Sell	-83,775	Closed	-$692K	–	272
2022 Q1	$692K	Buy	+83,775	New	+$677K	0.01%	260
2021 Q4	–	Sell	-402,961	Closed	-$9.07M	–	423
2021 Q3	$9.07M	Buy	402,961 +542	+0.1%	+$11.4K	0.05%	210
2021 Q2	$7.91M	Sell	402,419 -539,475	-57%	-$12.2M	0.04%	231
2021 Q1	$31.5M	Buy	+941,894	New	+$30.7M	0.17%	126

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Gilder Gagnon Howe & Co's SANA Position: Q2 2026 in Review

Gilder Gagnon Howe & Co reduced its Sana Biotechnology (SANA) stake by 6.1% in Q2 2026, selling an estimated $18.8K and leaving 89,960 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #269.

Gilder Gagnon Howe & Co first reported a position in SANA in Q1 2021 and has held it in 10 quarters since. The position peaked at $31.5M in Q1 2021. 212 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Gilder Gagnon Howe & Co held 89,960 shares of Sana Biotechnology worth $314K as of Q2 2026.
Gilder Gagnon Howe & Co sold 5,836 Sana Biotechnology shares in Q2 2026, an estimated $18.8K.
Sana Biotechnology made up ﹤0.01% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #269 holding.
Gilder Gagnon Howe & Co first reported a position in Sana Biotechnology in Q1 2021 and has held it in 10 quarters since.
Gilder Gagnon Howe & Co's Sana Biotechnology position peaked at $31.5M in Q1 2021.
212 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.